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Copper-zinc superoxide dismutase (SOD1) is a detoxifying enzyme localized in the cytosol, nucleus, peroxisomes, and mitochon-
dria. The discovery that mutationsin SOD1 gene cause a subset of familialamyotrophiclateral sclerosis (FALS) has attracted great
attention, andstudies to date havebeen mainlyfocused on discovering mutationsin the coding region andinvestigation at protein
level. Consideringthat changes in SOD1mRNA levels havebeen associated with sporadic ALS (SALS),a molecular understanding
of the processes involved in the regulation of SOD1 gene expression could not only unravel novel regulatory pathways that may
govern cellular phenotypes and changes in diseases but also might reveal therapeutic targets and treatments. This review seeks to
provide an overview of SOD1 gene structure and of the processes through which SOD1 transcription is controlled. Furthermore,
we emphasize the importance to focus future researches on investigating posttranscriptional mechanisms and their relevance to
ALS.
1.Introduction
Cu/Zn superoxide dismutase or SOD1 is a soluble pro-
tein acting as a 32kDa homodimeric enzyme to convert
naturally occurring, but harmful, superoxide radicals to
molecular oxygen and hydrogen peroxide. SOD1 is one of
the three human superoxide dismutases identiﬁed and char-
acterized in mammals: copper-zinc superoxide dismutase
(Cu/ZnSOD),manganese superoxide dismutase (MnSOD or
SOD2), and extracellular superoxide dismutase (ECSOD or
SOD3) [1]. When SOD1 was isolated for the ﬁrst time, it
was thought to be a copper storage protein [2]; the catalytic
function of SOD1 was discovered in 1969 by McCord and
Fridovich [3], and it was clear that SOD1 acts as a scav-
enger of superoxide, through a two-step reaction involving
reduction and reoxidation of the copper ion in its active site
[4]. Primarily, this reaction occurs in the cytoplasm where
SOD1 is highly expressed. However,˜immunohistochemical
analysis in rat hepatocytes identiﬁed SOD1 in other diﬀerent
subcellular organelles, such as nucleus, lysosomes, and mito-
chondria [5]. In the 1990s, the scientiﬁc community focused
theirstudies on the genetic and biochemical characterization
of SOD1 [6], demonstrating that SOD1 plays an important
role in diseases as heart failure [7], cancer [8], diabetes [9],
Down’s syndrome [10], and amyotrophic lateral sclerosis
[11]. In fact, in 1984, the ﬁrst paper about Down’s Syndrome
was published [12], and in 1993, the ﬁrst SOD1 gene
mutations associated with ALS were described [11]. In this
paper, we focused on SOD1 gene structure and organization,
transcriptional andpost-transcriptional generegulation,and
their contributions in the pathogenesis of ALS.
2.Gene Structureand Organization
The human SOD1 gene (Entrez Gene ID 6647) is located
on chromosome 21q22.11, and it codes for the monomeric
SOD1 polypeptide (153 amino acids, molecular weight
16kDa). More precisely, this gene is located from base pair
33,031,935 to base pair 33,041,241 with a genomic size of
9307bp, according to UCSC Genome Browser (GRCh37/
hg19; http://genome.ucsc.edu/). The coding region consists
of ﬁve exons interrupted by four introns (Figure 1). Several
polymorphisms have been identiﬁed in SOD1 gene, mainly
distributed in the regulatory regions, including promoter,2 Neurology Research International
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Figure 1: Genomic organization of human SOD1 gene. The size of exons and introns, in base pairs, is shown in association with each
fragment.The5  ﬂankingregionisexpanded, andthetranscriptionfactors,interactingwiththecorrespondingDNAregulatory elements,are
shownat the bottom. The transcription start site is depicted as an arrow at position +1.
UTRs, and introns. With regards to SOD1 mRNA splicing,
it has been demonstrated that the donor sequence at the
ﬁrst intron presents a T to C variant and, consequently, it
deviates from the highly conserved 5  GT... AG 3  consensus
sites. Nevertheless, it has been demonstrated that this
unconventional splice junction (5  GC... AG 3 )i sf u n c t i o n a l
[13].
The proximal promoter of human SOD1 gene, involved
in the basal transcription, has been well studied, and it
contains not only the TATA box, butalso a CCAATbox and a
GC-rich region, which are recognized by CCAAT/enhancer-
binding proteins (C/EBPs) and speciﬁcity protein 1 (Sp1),
respectively [14] .O t h e rb i n d i n gs i t e sf o rE g r 1 ,A P 1 ,A H R ,
Nrf2, NF-κB, and TR transcription factors have been also
identiﬁedandveriﬁedbyfunctionalstudies(Figure 1).These
transcription factors are involved in the regulation of SOD1
inducible gene expression under speciﬁc extra- and intracel-
lular conditions. Diﬀerent studies performed in rat cellular
lines have identiﬁed several other regulatory sequences in
the rat SOD1 promoter [15–18]. Considering that the rat
SOD1 gene is very similar to that of human, especially with
regard to the proximal part of the promoter region [18],
further eﬀorts will be necessary to identify possible other
regulatory elements in the human promoter. Moreover, in
view of the fact that regulatory elements can be located up to
several hundred kilobases away from the gene they control,
experiments should be carried out to test whether the long-
range control of transcription may represent a mechanism
involved in human SOD1 gene expression.
With regard to the 5  untranslated region (5 UTR),Sher-
man and colleagues [19]d e m o n s t r a t e dt h a tS O D 1m R N A
posseses various 5  termini, which are mapped by both
primer extension and Sl mapping. The authors showed that
the vast majority of the mRNA species has a 5  start site
located 23bp downstream the TATA box (TATAAA), while
the other mRNA molecules have 5  termini 30, 50, and
6 5 b pu p s t r e a mf r o mt h em a j o rt r a n s c r i p t i o ns t a r ts i t e .
Consequently, these mRNA species are produced through
TATA-independent transcription. It would be interesting
to perform in-depth investigations about the functional
relevance of these multiple transcription start sites, mainly
to determine the potential cell and tissue speciﬁcity of the
diﬀerent mRNA species.
Furthermore, two SOD1 mRNAs of about 0.7kb and
0.9kb have been identiﬁed in a variety of cells, and it
has been shown that they are transcribed from the same
gene and diﬀer in the length of their 3 UTRs caused by
multiple polyadenylation sites. Indeed, analysis of the DNA
sequence at the 3 UTR region of the SOD1 gene revealed
the presence of two groups of processing/polyadenylation
signals; the ﬁrst one contains two signals (AATAAA and
ATTAAA). The former is fused to the terminal portion of
the coding region and it is not utilized. On the contrary,
the second site (ATTAAA), localized 76bp downstream the
stop codon, is the one involved in the production of the
0.7kb mRNA [13]( Figure 2). The second group includes
three polyadenylation signals, located 200–250bp further
downstream; the middle one (AATAAA) is involved in the
formation of the 0.9kb SOD1 mRNA (Figure 2). Both the
mRNA species are functional, since they can be translated
in vitro to immunoprecipitable SOD1 proteins [19, 20]. The
longer transcript is approximately four times less abundant
than the 0.7kb mRNA.
3.TranscriptionalFactorsInvolved in
SOD1 ConstitutiveandInducibleExpression
Even if SOD1 has been often considered a “housekeeping
gene” due to its high and ubiquitous expression, it is now
clear that its induction is ﬁne-tuned modulated by complex
intracellular events which probably involve multiple positive
and negative regulatory elements acting in concert. Indeed,Neurology Research International 3
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Figure 2: Nucleotide sequence of the ﬁfth exon of SOD1 gene. The coding portion is highlighted in orange; the polyadenylation sites are in
red, and the A/U-rich elements are in green.
the diversity of SOD1 inducers means that there are multiple
cis-acting elements for this gene, and many studies have
been performed to precisely identify the location and the
functional relevance of both these DNA sequences and the
corresponding trans-acting factors.
3.1.C/EBPs(CCAAT/EnhancerBinding Proteins). These pro-
teins are a family of transcription factors, all containing a
highly conserved, basic leucine zipper (bZIP) domain at the
C-terminus. It has been demonstrated that C/EBP-related
factors are necessary for SOD1 constitutive expression; both
C/EBPα and C/EBPβ can interact with the CAAT box
(located at position –64 to –55 from transcription start site),
playing similar and nonmutually exclusive roles on SOD1
basal transcription [21]. This C/EBP consensus element
partially overlaps the Sp1/Egr1 sequence, suggesting that an
interlacednetworkamongthesetranscriptionfactorsmayact
in the ﬁne control of regulation of SOD1 gene expression.
Furthermore, it has been recently demonstrated that
also the transcription factor CCAAT/enhancer binding pro-
tein delta (CEBPD, C/EBPδ,N F - I L 6 β)i si n v o l v e di nt h e
regulation of human SOD1 transcription [22]. Speciﬁcally,
CEBPD enhances SOD1 mRNA expression in cisplatin-
treated human urothelial carcinoma cell line (NTUB1) via
direct promoter transactivation.
3.2. Sp1 (Speciﬁcity Protein 1). Sp1 is a ubiquitously ex-
pressed C2H2-type zinc ﬁnger-containing DNA binding
protein. It binds GC-rich motifs (such as 5 -G/T-GGGCGG-
G/A-G/A-C/T-3  or 5 -G/T-G/A-GGCG-G/T-G/A-G/A-C/T-
3 ) with high aﬃnity and enhances transcription with one of
the two glutamine-rich domains [23]. It has been demon-
strated that overexpression of Sp1 conspicuously enhances
SOD1 basal promoter activity [24].
3.3. Egr1 (Early Growth Response-1). Egr1 is a nuclear phos-
phoprotein of 80kDa that functions as a regulator of
transcription and belongs to the family of early response
genes; it is rapidly induced by mitogens to transduce the
proliferative signal. It has also been demonstrated that
cytokines and stress signals such as radiation, injury, and
oxidative or mechanical stress can induce the expression of
this transcription factor [25–29]. In a paper published by
Minc and coworkers [30], it has been demonstrated that
SOD1 mRNA level is rapidly increased after the treatment
of HeLa cells with phorbol-12-myristate-13-acetate (PMA),
and the region between nucleotides −59 and −48 has been
identiﬁed as the one responsible for PMA-induced expres-
sion. This region presents noncanonical consensus recogni-
tion sequences for Sp1 and Egr-1, and it is bound by Sp1
in a constitutive manner and by Egr1 in response to PMA
exposure.
3.4. AP1 (Activating Protein 1). AP-1 is a homo- or het-
erodimeric transcription factor made by proteins from Jun,
Fos, and Maf subfamilies. Activating transcription factor
(ATF) proteins also belong to AP1. All these proteins are
basicleucinezipper(bZIP)transcriptionfactors. Theactivity
of AP-1 proteins can be regulated by a broad range of
environmental cues, including growth factors, cytokines,
and oxidative stress, which initiate a variety of intracellular
pathwaystotransduce theinformationfromtheextracellular
milieu to the nuclear compartment, thus leading to speciﬁc
cellular responses.
It has been demonstrated that AP1 represses SOD1 tran-
scription by sequestrating essential coactivators, such as Sp1,
rather than interacting directly with SOD1 gene promoter
[24].
Furthermore, in agreement with the previous results
demonstrating AP1 transcriptional repression activity, it has
been shown that neuronal nitric oxide synthase (nNOS)
over-expressioncausesthedownregulationofSOD1interms
of mRNA, protein, and activity levels [31] and that this
is caused by two events: the decreased binding of Sp1 to4 Neurology Research International
SOD1 promoter, caused by nNOS interaction with Sp1, and
a concomitant increased binding activity of AP1 to the same
site.
3.5. AHR (Aryl Hydrocarbon Receptor). AHR is a ligand-
activated transcription factor belonging to the helix-loop-
helix (bHLH) family. It is well known that, prior to ligand
binding, AHR exists in a latent state in the cytosol associated
with HSP90 and HSP90 accessory proteins [32–34]. The
interaction with HSP90 is fundamental to retain AHR in the
cytoplasm. Many synthetic halogenated and nonhalogenated
aromatichydrocarbonsactivateAHRsignalpathwaythrough
a direct interaction: upon ligand binding, HSP90-bound
AHR translocates into the nucleus where it exchanges
HSP90 for another bHLH protein, known as hydrocarbon
receptornucleartranslocator(Arnt).Thisnewheterodimeric
complex binds to the xenobiotic responsive element (XRE)
thatfunctionsasacis-actingenhancerinthepromoterregion
of numerous phase I and II drug-metabolizing enzyme genes
[35, 36]. Cho and coworkers [37] observed an increased
expression of SOD1 mRNA and protein after the exposure
of human HepG2 and HeLa cells to one of the most
toxic man-made hazard, the 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), an environmental contaminant belonging
to the halogenated aromatic hydrocarbons class and inter-
acting with AHR. The authors identiﬁed the presence of a
xenobiotic responsive element in the 5
 ﬂanking region of
human SOD1 gene (located between −255 and −238 from
the transcription start site), which is responsible for the
induction by TCDD.
3.6. Nrf2 (Nuclear Factor E2-Related Factor 2). Nrf2 is a
Cap n collar (Cnc) transcription factor that regulates the
expression and the coordinated induction of a battery of
defensive genes encoding phase II detoxifying enzymes and
antioxidant proteins. The activity ofNrf2 iscontrolled by the
cysteine-rich cytosolic INrf2 (Inhibitor of Nrf2), also known
as Keap1 (Kelch-like ECH-associated protein1). The activa-
tion of Nrf2 pathway requires its cytosolic stabilization via
oxidative modiﬁcation of distinct Keap1 cysteine residues,
Keap1 preoteasomal degradation, and/or phosphorylation
of Nrf2. The dissociation from Keap1 is a prerequisite for
Nrf2 translocation to the nucleus. In this compartment,
Nrf2 heterodimerizes with a small Maf protein and binds
to the cis-acting antioxidant/electrophile responsive element
(ARE/EpRE), activating the transcription of various cyto-
protective genes involved in detoxiﬁcation from xenobiotics,
electrophile conjugation, ROS scavenging, and regulation of
intracellular redox homeostasis [38–41].
An antioxidant responsive element (located between
−356 and −330 from the transcription start site) has been
identiﬁed in human SOD1 gene promoter [42, 43]. Park
andcolleaguesdemonstratedthatSOD1genetranscriptionis
inducedin human HepG2hepatoma cellsafter the treatment
with the dioxin TCDD, which produces reactive oxygen
species thus leading to the activation of Nrf2 signalling.
Moreover,ithasbeenshownthatlow-doseandnontoxicpro-
teasome inhibition enhances mRNA and protein expression
ofSOD1indiﬀerenthumanendothelialandvascularsmooth
muscle cells through transcriptional induction mediated by
Nrf2 [43].
3.7. NF-κB (Nuclear Factor-KappaB). The term NF-κB refers
to a family of ﬁve structurally related transcription factors
(p50, p52, RelA/p65, c-Rel, and RelB), all containing the Rel
homology domain (RHD)within the N-terminus and acting
as homo- and heterodimeric DNA binding complexes [44].
Their functionality andnuclear localization arecontrolled by
a family of inhibitor proteins, known as IkappaBs (IκBs). In
nonstimulated cells, NF-κB dimers are bound to inhibitory
IκB proteins and are thereby sequestered in the cytoplasm
as inactive complexes. Several studies showed that NF-κB
activity is induced in most cell types in response to a broad
variety of stimuli, ranging from cytokines, radiation, and
oxidative stress (such as exposure to H2O2), with major roles
incoordinatinginnateandadaptiveimmunity,cellactivation
and proliferation, survival, development, and apoptosis [45,
46]. NF-κB was one of the ﬁrst transcription factors shown
to be redox regulated [47–50], and Rojo and colleagues [51]
showed that cell treatment with H2O2initiates the PI3K/Akt
cascades, which participates in NF-κB activation and in
subsequent SOD1 transcriptional induction. Indeed, the
authors identiﬁed a p65-NF-κB binding site in the human
SOD1 promoter (GGTAAGTCCC), and they demonstrated
that Akt-activated NF-κB presents increased binding to this
sequence, mediating the upregulation of SOD1 expression.
3.8. TRs (Thyroid Hormone Receptors). The thyroid hor-
mone receptors are encoded by the TRalpha and TRbeta
genes and are ligand-dependent transcription factors, since
they bind both thyroid hormones (THs) and TH-response
elements (TREs) that are located in the promoters of
target genes. These proteins, which belong to the nuclear
receptor superfamily, regulate development and a broad
variety of critical cellular functions including growth, diﬀer-
entiation, basal metabolic rate, and metabolism of protein,
fat, and carbohydrate. It has been demonstrated that TRs
can either enhance or repress transcription. Hormone-
dependent repression requires binding to negative TREs
(nTREs); in particular, the unoccupied receptor increases
transcription on nTREs, and ligand binding to TR reverses
this induction [52]. The responsive sites of these negatively
regulated genes are generally localized to the proximal
promoter region [53]. In agreement with this observation,
Santos and co-workers [54] have identiﬁed a thyroid hor-
mone inhibitory element between −157 and +17 of the
human SOD1 promoter and demonstrated that T3 exposure
reverses the induction of SOD1 transcription caused by
the ROS-producing paraquat and PMA agents, through
the direct TR/T3-DNA interaction. On the contrary, SOD1
promoter is signiﬁcantly upregulated by unliganded TRs.
4.PosttranscriptionalGene Regulation
Historically, eﬀorts aimed at decoding the molecular mech-
anism of gene expression have been principally focused onNeurology Research International 5
transcriptional control. However, post-transcriptional regu-
lation of mRNAs is now considered as an important step in
the ﬂow of genetic information providing additional oppor-
tunities by which gene expression could be rapidly mod-
ulated. Indeed, post-transcriptional events such as mRNA
processing and nuclear export, mRNA stability, translational
eﬃciency, and microRNA-dependent modulation create a
complex intracellular network contributing to determine the
global levels of speciﬁc mRNAs. Most mRNA regulatory
elements are located within the 5  and 3 UTRs, where they
function as platforms for the binding of numerous proteins
and noncoding RNAs. The 5 UTR is principally involved
in controlling mRNA translation [55], while the 3 UTR
regulates multiple steps of mRNA metabolism and stability.
Very few works on post-transcriptional regulation of
SOD1 have been published so far.
As mentioned above, two species of SOD1 mRNA with
diﬀerent 3 UTR lengths have been identiﬁed, and they pro-
duce in vitro diﬀerent quantities of SOD1 protein. Kilk
and colleagues [56] performed functional study to investi-
gate the eﬀect of this regulatory region on SOD1 protein
expression, and they observed that cells transfected with
a long cDNA, containing the long 3 UTR, produce three
times more SOD1 protein than cells transfected with a
cDNA presenting a deletion of the last 185bp from the
3 UTR. The authors hypothesized that the ability of the
long mRNA to produce more SOD1 enzyme may depend on
speciﬁc sequences located in the 3 UTR, and they identiﬁed
the presence of various A/U-rich elements (AREs) in this
region (AUUUA, CUUUA, AUUUG, GUUUUA, AUUUU,
and AUUUC) (Figure 2). AREs were initially deﬁned by
t h es e q u e n c eA U U U A[ 57], although subsequent studies
showed other sequences with U-stretches presenting the
same properties as the canonical element. Several ARE-
binding proteins, which function as trans-acting factors,
have been identiﬁed, and interaction of these proteins can
correlate negatively or positively with the stability and the
translatability of the target mRNA [58]. Considering the
biological relevance of these sequences, the identiﬁcation
of the proteins potentially interacting with SOD1 mRNA
may shed new light on SOD1 gene expression modulation.
Moreover, another important question is whether these
SOD1 mRNA species, diﬀering for their 3 UTR lengths,
could be somehow linked to pathological conditions, since it
is possible that speciﬁc cellular stresses may vary the relative
proportions of such variants with relevant implications for
cell phenotypes.
In addition, also SOD1 post-transcriptional regulation
mediated by microRNAs (miRNAs) represents a ﬁeld still
almost unexplored. miRNAs, which are small non-protein-
coding RNAs,functionas keypost-transcriptional regulators
ofgeneexpressionbyusuallybasepairingtothe3 UTRofthe
target mRNAs to cause translational repression and mRNA
decay [59, 60]. Recently, Wang and co-workers [61]s h o w e d ,
through computational and biological approaches, that
SOD1 is a target of miR-377 in human and mouse mesangial
cells and miR-377 diminished SOD1 protein levels. Owing
to the importance of miRNAsin mRNAmetabolism control,
future in-depth researches should be carried out in this ﬁeld
to unravel previously unrecognized complex regulatory and
interactive pathways that may cooperate to modulate SOD1
quantities and whose dysregulation may be relevant for ALS
disease states.
5.AmyotrophicLateralSclerosis
Amyotrophic lateral sclerosis disease (ALS) is a multifactor
and multigenic disorder with still unknown aetiology and
pathogenesis. Even if several new genes associated to ALS
havebeendescribed,SOD1geneisconsideredthemajorgene
involved in ALS pathogenesis.
5.1. Genetic Variants. In 1991, Siddique and collaborators
[62] identiﬁed a linkage of familial ALS to the SOD1 locus
on chromosome 21q22 and demonstrated genetic locus
heterogeneity in FALS studying 23 ALS families. In 1993,
Rosen [11] and collaborators have reported tight genetic
linkage between ALS and SOD1 gene, establishing SOD1
as the ﬁrst causative gene for ALS (genetic nomenclature,
ALS1). Mutations in SOD1 gene are responsible for 12–
23% of all FALS cases [63, 64]. More than 150 SOD1
mutationshavebeenreportedin68ofthe153codons,spread
over all ﬁve exons (ALS Online Genetic Database, ALSOD:
http://alsod.iop.kcl.ac.uk/)[ 65], most of them cause disease.
Although most mutations are missense, nonsense mutations
and deletions have also been found [66, 67]. SOD1 exonic
mutations have occasionally been described in patients with
apparently sporadic onset, and it has been estimated that
1% of SALS could be due to SOD1 mutations [68]. Many of
the mutations are at present unique to individual families.
Correlation between mutations and phenotype has been
investigated, because of a large variability in phenotype in
term of disease progression, extramotor features, and age of
onset but is generally diﬃcult to predict on the basis of the
SOD1 mutations [66].
5.2. SOD1 Gene Expression in ALS. Even if SOD1 gene has
been considered fundamental in ALS, numerous studies
have been done concerning protein expression and gene
mutations, but mRNA level studies are very rare. For the
ﬁrst time, in 1997, Nishiyama studied SOD1 expression in
cervical and spinal cord of ALS patients using a quanti-
tative in situ hybridization technique [69]. There were no
signiﬁcant diﬀerences between the amounts of SOD1 mRNA
level observed in patients with sporadic or familial disease,
and normal control subjects. Moreover, motoneurons in the
normal spinal ventral horn and precentral motor cortex
exhibited signiﬁcantly higher levelsof SOD1messenger RNA
than did other neurons [69]. In recent years, expression
studies often produced conﬂicting data about up- or down-
regulation of ALS relevant genes, such as SOD1 [70–72].
The confounding data were probably due to diﬀerences in
the central nervous system (CNS) tissue areas analyzed and
possibly diﬀerences in the analytical techniques used.
The latest SOD1 gene expression study demonstrated
that SOD1 mRNA level is elevated in speciﬁc nervous
areas typically aﬀected by ALS disease (i.e., brain stem and6 Neurology Research International
spinal cord) and not in other brain areas not involved in
the neurodegenerative process (i.e., cerebellum and cerebral
cortex) in SALS patients [73]. Moreover, increased SOD1
mRNA expression has been detected in peripheral system
as lymphocytes from SALS patients compared to healthy
people [73]. However, in the same work, Western Blotting
analysis showed lower or similar expression of the protein
both in lymphocytes and in nervous tissue-aﬀected areas
thus conﬁrming a previous observation obtained in the
peripheral cells [74]. On the contrary, histopathological
analysis of spinal cord tissue from SALS patients evidenced
an increased SOD1 protein expression compared with
controls. This result correlates with the evidence of higher
mRNA level and suggests the hypothesis that, in at least
a subgroup of SALS patients, misfolded and aggregated
SOD1 protein would precipitate in the insoluble fraction
becoming undetectable after extraction with routinely used
lysis buﬀers. Actually, proteinaceous inclusion bodies that
may contain SOD1 have been already described in motor
neurons of SALS patients [75–77], and the presence of
aberrant SOD1 species associated with human sporadic
ALS has been extensively demonstrated [78–80]. Insoluble
SOD1-containing aggregates are also a characteristic of
the familial ALS linked to SOD1 mutation. In mutSOD1
transgenic mouse, the detergent-insoluble accumulation of
SOD1 appears before or coincident with symptom onset
[81],and inthehumanSOD1-associated ALS,mutantSOD1
aggregation is a pathological hallmark [82]. This feature
common to familial and sporadic cases suggests a shared
pathological trait.
6.Conclusions
Considering the few literature data about SOD1 gene regula-
tion, it appears clear the importance of understanding how
the expression of this gene can be controlled and modulated
in normal and ALS pathological conditions. The molecular
pathways regulating SOD1 expression at the transcriptional
level have been studied, and many cis-elements and the
relative trans-acting protein factors have been identiﬁed.
Nevertheless, the details of most of these interactions and
the in vivo consequences of their modulation for the
most part are yet to be determined, mainly in relation
to pathological states. Moreover, also post-transcriptional
mechanisms may exert important functions in determining
the global levels of functional SOD1. Indeed, the formation
of speciﬁc ribonucleoprotein complexes and RNA-silencing
events may provide additional mechanisms by which SOD1
expression could be rapidly and precisely modulated. In
particular, considering that microRNAs are emerging as
master regulators of gene expression due to their capability
to ﬁnely tune gene dosage, investigation in this ﬁeld should
become a preferred topic for new researches. Future gain
of knowledge about these processes may help to discover
previously unanticipated integrated networks, leading to
new and exciting directions in the ﬁeld of ALS medical
research with promising prospects. Indeed, the progress in
understanding the mechanisms of transcriptional and post-
transcriptional control could oﬀerhope for the development
of new-generation drugs or medical treatment strategies.
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